Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

Part of paid clinical trials in Boston, Massachusetts.

Sponsor: Massachusetts General Hospital
Study ID: NCT00642759
Phase: PHASE2
Status: Completed

Conditions

Non-small Cell Lung Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

carboplatin — DRUG
Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
Nab-paclitaxel — DRUG
Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
Bevacizumab — DRUG
IV infusion

Study Details

The purpose of this research study is to learn more about whether the combination of drugs carboplatin, Abraxane and Avastin helps treat non-small cell lung cancer (NSCLC). One of the standard treatments for advanced NSCLC is the combination of the drugs carboplatin, paclitaxel and Avastin. Paclitaxel can be associated with severe side effects that may make the treatment difficult to tolerate. Some of these side effects are caused by the solution used to dissolve paclitaxel before it can be administered. Abraxane is a different form of paclitaxel that does not need to be dissolved by this solution. Abraxane is approved for the treatment of breast cancer but is not approved to treat NSCLC. We will also be trying to learn more about how the drug Avastin may work to treat cancer.